TESARO (TSRO) PT Raised to $67.00

TESARO (NASDAQ:TSRO) had its price target upped by Wedbush from $60.00 to $67.00 in a research note published on Friday, November 2nd. They currently have an outperform rating on the biopharmaceutical company’s stock.

TSRO has been the topic of a number of other research reports. BidaskClub upgraded shares of TESARO from a buy rating to a strong-buy rating in a research note on Friday, October 19th. ValuEngine lowered shares of TESARO from a hold rating to a sell rating in a research note on Saturday, July 28th. Cowen reiterated a hold rating and issued a $38.00 price target on shares of TESARO in a research note on Monday, October 22nd. Bank of America lowered shares of TESARO from a buy rating to a neutral rating in a research note on Monday, August 6th. Finally, HC Wainwright decreased their price target on shares of TESARO to $71.00 and set a buy rating on the stock in a research note on Friday, July 20th. Nine investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. TESARO presently has an average rating of Buy and a consensus target price of $78.00.

Shares of TESARO stock traded down $5.81 during trading on Friday, hitting $25.10. 3,864,261 shares of the stock were exchanged, compared to its average volume of 1,985,593. TESARO has a 1-year low of $23.41 and a 1-year high of $92.71. The company has a debt-to-equity ratio of 3.74, a quick ratio of 3.64 and a current ratio of 3.40.

TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share for the quarter, topping the consensus estimate of ($2.62) by $0.13. The company had revenue of $64.40 million for the quarter, compared to analyst estimates of $71.84 million. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. TESARO’s revenue for the quarter was down 54.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.47) EPS. As a group, research analysts predict that TESARO will post -10.97 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in TSRO. Russell Investments Group Ltd. grew its position in shares of TESARO by 54.1% during the 1st quarter. Russell Investments Group Ltd. now owns 8,498 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 2,985 shares in the last quarter. Stifel Financial Corp acquired a new position in shares of TESARO during the 1st quarter worth approximately $241,000. Guggenheim Capital LLC grew its position in shares of TESARO by 15.1% during the 1st quarter. Guggenheim Capital LLC now owns 54,803 shares of the biopharmaceutical company’s stock worth $3,131,000 after purchasing an additional 7,184 shares in the last quarter. Legal & General Group Plc grew its position in shares of TESARO by 17.5% during the 1st quarter. Legal & General Group Plc now owns 43,656 shares of the biopharmaceutical company’s stock worth $2,495,000 after purchasing an additional 6,517 shares in the last quarter. Finally, Xact Kapitalforvaltning AB grew its position in shares of TESARO by 86.8% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 6,700 shares of the biopharmaceutical company’s stock worth $298,000 after purchasing an additional 3,113 shares in the last quarter.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Further Reading: Retained Earnings

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply